Physician profile
Asma E Ali
NPI 1497737936
$555.41
in general payments reported to CMS, 2019-2025
9 companies · $148 in 2025
The $148 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $120 · 2021: $61.61 · 2022: $17.82 · 2023: $113 · 2024: $95.67 · 2025: $148.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $356.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $137.67 | 2020-2023 | Mounjaro |
| Novo Nordisk INC | $133.21 | 2020-2025 | Ozempic, Rybelsus |
| Regeneron Healthcare Solutions, INC. | $70.53 | 2023-2024 | Dupixent |
| Vanda Pharmaceuticals INC. | $65.79 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $44.17 | 2023 | Bylvay |
| Takeda Pharmaceuticals U.S.A., INC. | $40.75 | 2024-2025 | Gattex, Eohilia |
| Nestle Healthcare Nutrition INC. | $22.25 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $21.62 | 2025 | |
| Alcresta Therapeutics, INC. | $19.42 | 2025 | Relizorb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Asma Ali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.